Inhibikase Therapeutics (IKT) Profit After Tax (2020 - 2026)

Inhibikase Therapeutics (IKT) has reported Profit After Tax for 7 consecutive years, with -$16.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 19.75% year-over-year to -$16.4 million; the TTM figure through Mar 2026 stood at -$51.0 million (down 39.43% YoY), while the FY2025 annual figure was -$48.3 million, down 75.36% from the prior year.
• Profit After Tax slipped to -$16.4 million in Q1 2026 per IKT's latest filing, from -$12.7 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$4.2 million in Q4 2023 and bottomed at -$16.4 million in Q1 2026.
• Historically, Profit After Tax has averaged -$7.6 million across 5 years, with a median of -$5.0 million in 2024.
• Annual changes were most pronounced in 2022 — Profit After Tax climbed 15.13% — and 2025, when it sank 194.19%.
• Inhibikase Therapeutics' Profit After Tax stood at -$4.3 million in 2022, then climbed by 2.36% to -$4.2 million in 2023, then sank by 190.4% to -$12.1 million in 2024, then retreated by 4.96% to -$12.7 million in 2025, then decreased by 28.63% to -$16.4 million in 2026.
• Business Quant data shows IKT's Profit After Tax at -$16.4 million in Q1 2026, -$12.7 million in Q4 2025, and -$11.9 million in Q3 2025.